Gay, Bisexual Men Report Higher Rates of Skin Cancer Than Heterosexual Men
the ONA take:
Gay and bisexual men indoor tan more frequently and report higher rates of skin cancer than heterosexual men, a new study published online ahead of print in JAMA Dermatology has shown.
Because indoor tanning, which is highly associated with skin cancer, has been suggested to be more common among sexual minority men compared with heterosexual men, researchers sought to evaluate whether skin cancer prevalence and indoor tanning behaviors differ by sexual orientation.
For the cross-sectional study, researchers analyzed data from the 2001, 2003, 2005, and 2009 California Health Interview Surveys and the 2013 National Health Interview Survey.
A total of 192,575 men and women 18 years or older identified as heterosexual or a sexual minority (homosexual, gay, or bisexual). Of those, 78,487 were heterosexual men, 3,083 were sexual minority men, 107,976 were heterosexual women, and 3,029 were sexual minority women.
Results showed that sexual minority men were more likely than heterosexual men to report having skin cancer and having tanned indoors, while sexual minority women were less likely than heterosexual women to report having tanned indoors and having had nonmelanoma skin cancer.
“Our hope is that this finding will help increase awareness among health care providers that gay and bisexual men constitute a high-risk population for skin cancer, which in turn will lead to increased public health education and more diligent skin cancer screening in this group of men,” Sarah Arron, MD, PhD, a UCSF associate professor of dermatology, said.
“Recent research suggests that, fortunately, screening can increase early detection and decrease mortality from this disease.”
Gay and bisexual men indoor tan more frequently and report higher rates of skin cancer than heterosexual men.
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Longer Maintenance Therapy Duration May Improve Survival in Myeloma
- HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma
- Economic Evaluation of Obinutuzumab in Combination With Chlorambucil in First-line Treatment of Patients With Chronic Lymphocytic Leukemia in Spain
- MRD Assessment Improves PFS Prediction in Patients With CLL
- Cancer Patients Have Unrealistic Hopes When Entering Clinical Trials
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|